Nano Pharmaceuticals
Market Cap
₹96 ₹96.00 Cr.
P/E
47.23
PEG = P/E ÷ 5yr forward EPS CAGR

The forward EPS CAGR is estimated individually for each company - factoring in its guidance, industry, and growth drivers - not generic rule-based projection.

Key Ratios

Debt to Equity
Debt to Equity
0.56
Div Yield (%)
Div Yield (%)
-
Individual < 2 lac
Individual < 2 lac
19.04 %
Institutions
Institutions
-
Market cap
Market cap
96.00 Cr
No. of Shareholders
No. of Shareholders
4,435
OPM (%)
OPM (%)
6.77 %
PE
PE
47.23
Prom Holding
Prom Holding
45.08 %
ROCE (%)
ROCE (%)
6.98
ROE (%)
ROE (%)
0.99
Sales
Sales
86.11 Cr
  • Concord Drugs
  • Veerhealth Care
  • Sotac Pharmaceutical
Last updated on 25 Sep 2026
  • Concord Drugs makes pharmaceutical formulations at its Hyderabad plant. It sells only in India with no exports. It consolidates its wholly owned formulations subsidiary, Proton Remedies.
  • It buys inputs from its API associate, Cortex Laboratories, and its pharma associate, Seelam Laboratories. Its formulations subsidiary, Proton Remedies, adds almost no profit.
  • It funds working capital and expansion with a preferential share and warrant programme. Part of the warrant money is still to come.
  • First-quarter revenue was Rs20.95Cr with profit of Rs1.11Cr. That profit already beat full FY26 profit. The margin was well above the thin full-year level.
  • Receivables rose to Rs24.38Cr from Rs13.60Cr. Operating cash flow stayed negative despite profit.
  • Near-term profit depends on holding the 74% FY26 revenue jump.
  • Promoters hold over half the shares. Related-party limits go to a yearly shareholder vote.
  • Related-party trade limits FY27
    each line allows up to Rs15Cr, about 19% of FY26 revenue. Actual purchases and sales will show use against limits.
  • Sustenance of Q1 profit jump ~mid-Nov 2026
    the print shows if Q1 revenue pace and higher margin hold. It also shows the receivables move.
  • Remaining preferential warrants up to May 2027
    full conversion adds 20.25L shares, about 15% dilution. It brings the rest of the money for working capital and expansion.
  • Old income-tax demand No timeline
    the case decides if Rs2.59Cr becomes payable. The company expects no outflow.
Price Range

See where the stock is trading versus its 52-week high and low.

Low
61
52W Range
High
93
Timeline

Key company specific updates.

Custom financial statement

Edit rows

Forensics

7 Yes

Positive for this company

1 Neutral

Neutral for this company

8 No

Negative for this company

1 No Data

Insufficient data to analyse

Revenue mix

Product Wise Break-Up

Peer Comparison

FAQs on Concord Drugs Ltd. Business

Concord Drugs Limited, founded in 1995, is a leading pharmaceutical company in India. Specializing in generics, branded, and specialty pharmaceuticals, Concord is known for its diverse product portfolio of over 200 prescription and over-the-counter products.

Concord Drugs major competitors are Veerhealth Care, Sotac Pharmaceutical, Parmax Pharma, Pharmaids Pharma, Asston Pharma, Denis Chem Lab, Makers Laboratories.
Market Cap of Concord Drugs is ₹100 Crs.
While the median market cap of its peers are ₹100 Crs.

Concord Drugs seems to be financially stable compared to its competitors.
The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.

Company Filing

2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
Annual Report FY26 FY25 FY24 FY23 FY22 FY21 FY20 FY19 FY18 FY17 FY16 FY15 FY14 FY13 FY12 FY11 FY10
Earnings Release
Investor Presentation
Conference Call
Conference Call SummaryCon Call Summary

Discussions & Analysis

Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material